Literature DB >> 9181393

Fluconazole concentrations in pulmonary tissue and pericardial fluid.

C M Rieder-Nelissen1, J Hasse, R A Yeates, E Sarnow.   

Abstract

In order to investigate the clinical efficacy of the triazole antifungal agent fluconazole (FCA) in the treatment of pulmonary mycosis, in the present study the concentrations of fluconazole in human pulmonary tissue, pericardial fluid and serum were determined at 1, 2, 12 and 13 h after intravenous administration of fluconazole 200 mg. The mean FCA concentrations in the serum were 4.04 mg/l (1 h), 3.82 mg/l (2 h), 2.35 mg/l (12 h) and 2.13 mg/l (13 h). The respective FCA levels in the pulmonary tissue were 4.64 mg/kg, 4.54 mg/kg; 3.50 mg/kg and 3.40 mg/kg and the concentrations in the pericardial fluid were 3.86 mg/l, 3.57 mg/l, 2.35 mg/l and 2.13 mg/l. The FCA concentrations in the pulmonary tissue that were statistically significant higher than the serum concentrations were found at 2 h, 12 h and 13 h after intravenous administration (p < 0.05).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181393     DOI: 10.1007/BF02113615

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

2.  Sputum levels of fluconazole in humans.

Authors:  P Ebden; P Neill; P R Farrow
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  Comparative activities of UK-49,858 and amphotericin B against Blastomyces dermatitidis infections in mice.

Authors:  C A Lyman; A M Sugar; R D Diamond
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

4.  Gas chromatographic method for the determination of fluconazole, a novel antifungal agent, in human plasma and urine.

Authors:  P R Wood; M H Tarbit
Journal:  J Chromatogr       Date:  1986-11-28

Review 5.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

6.  Pharmacokinetics and tissue penetration of fluconazole in rabbits.

Authors:  T J Walsh; G Foulds; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group.

Authors:  A Catanzaro; J N Galgiani; B E Levine; P K Sharkey-Mathis; J Fierer; D A Stevens; S W Chapman; G Cloud
Journal:  Am J Med       Date:  1995-03       Impact factor: 4.965

8.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

9.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

  9 in total
  3 in total

Review 1.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

2.  Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.

Authors:  Suheyla S Senger; George R Thompson; Palash Samanta; Jillian Ahrens; Cornelius J Clancy; M Hong Nguyen
Journal:  Open Forum Infect Dis       Date:  2021-04-17       Impact factor: 3.835

3.  Candida glabrata Empyema Thoracis-A Post-COVID-19 Complication.

Authors:  Neeraja Swaminathan; Katherine Anderson; Joshua D Nosanchuk; Matthew J Akiyama
Journal:  J Fungi (Basel)       Date:  2022-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.